ClexBio

About the solution

Founded by Armend Håti, ClexBio is a biotechnology company developing the next generation of tissue therapies to address chronic diseases, starting with liver disease. Their platform leverages a multicomponent approach, combining three different cell types to create functional, long-lasting tissue structures that closely mimic human biology. This approach offers new hope in regenerative medicine, with the potential to revolutionize treatment options for patients who face limited alternatives, such as those requiring liver transplants.

ClexBio’s solution tackles two major challenges in healthcare: the limited efficacy of current cell and tissue therapies and the strain on healthcare systems from a multitude of chronic diseases. By focusing on liver tissue as a starting point, ClexBio aims to restore function in end-stage liver failure patients, offering a treatment with long-term functionality and improved therapeutic performance. This breakthrough technology has significant potential to disrupt and improve therapeutic treatment options across a wide range of chronic diseases.

EQT Foundation’s Investment

EQT Foundation’s investment in ClexBio will help to expand product development operations and accelerate preclinical studies. Our investment is supported by introductions to advisors within the EQT Life Sciences network, relevant research institutions, and EQT portfolio companies in the pharmaceutical and therapeutic sectors.